张宏
1.姓名、职称等头衔
张宏、研究员，博士生导师 zhanghong@shutcm.edu.cn
男，研究生学历，理学博士，研究员，博士生导师。国家科技专家库成员，上海市科学技术专家库成员，国家自然科学基金评审专家，教育部学位与研究生教育发展中心评审专家， sci期刊current pharmaceutical design编委和frontiers in pharmacology客座编辑，theranostics、international journal of biological sciences、phytomedicine、phytotherapy research、journal of ethnopharmacology等杂志审稿人。
长期从事组分中药发现及配伍机制研究，主持完成的《疤痕止痒软化膏防治增生性瘢痕的有效组分、作用机制及临床疗效》获2015年度上海市浦东新区科技进步二等奖。在此基础上，进一步提出基于成分配伍的组分中药（成分中药）研究策略（journal of ethnopharmacology, 2020, 254:112687. if=5.195，2区，引用51次），并以抗肿瘤复方中成药艾迪注射液为例进行了示范性研究（phytomedicine, 2022, 103:154231. if=6.656，1区），为清楚阐释方剂配伍理论的现代科学内涵（中医药领域重大前沿科学问题之一）奠定了基础。
先后主持承担国家重点研发计划、国家自然科学基金及上海市课题等20余项。第一完成人获得上海市浦东新区科技进步二等奖1项；授权发明专利11项；出版教材和专著，副主编4部，编委6部；发表论文150余篇，其中作为第一作者或通讯作者sci论文82篇、核心期刊35篇，if>5.0 sci论文31篇，总引用4800余次，2篇入选esi全球高被引论文；h指数39。
2.近五年以第一负责人承担的科研课题与经费：
[1] 国家自然科学基金面上项目，中药苦荞头有效成分tatariside f靶向mzf1/lncrna hclnc1/odc1通路抗肝癌的分子机制研究，2022/01-2025/12，55万元，在研，主持
[2] 国家重点研发计划子课题，三种小血管病“异病同证”物质基础及复方“异病同治”药理作用研,究2019/12-2022/06，216万元，结题，主持
[3] 国家自然科学基金面上项目，基于细胞热转移分析技术的蔓荆呋喃诱导宫颈癌细胞凋亡分子靶点研究，2018/01-2021/12，55万元，结题，主持
[4] 上海市科委科技创新行动计划项目，中药六类新药冬柏通淋颗粒的临床前研究，2015/07-2018/09，120万元，结题，主持
[5] 上海市科委科技创新行动计划项目，组分中药祛瘢灵治疗增生性瘢痕的成药性研究，2015/07-2018/09，50万元，结题，主持
[6] 浦东新区领先人才项目，pwr12015-05，蔓荆呋喃诱导宫颈癌细胞凋亡的分子靶点研究，2016/01-2019/12，60万元，结题，主持
[7] 浦东新区科委项目，pkj2015-y13，卵巢癌分子诊断标志物的筛选研究，2015/08-2018/07，28万元，结题，主持
3. 第一/通讯作者代表性论文(近5年)
[1] qiu-ping liu, yu-ying chen, pei an, khalid rahman, xin luan*, hong zhang*. natural products targeting macrophages in tumor microenvironment are a source of potential antitumor agents. phytomedicine, 2023, 109: 154612. (if=6.656)
[2] hong-xuan yang, qiu-ping liu, yan-xi zhou, yu-ying chen, pei an, yi-zhuo xing, lei zhang*, min jia* and hong zhang*. forsythiasides: a review of the pharmacological effects. frontiers in cardiovascular medicine, 2022, 9:971491. (if=5.846)
[3] qiu-ping liu†, yu-ying chen†, yuan-yuan yu†, pei an, yi-zhuo xing, hong-xuan yang, yin-jian zhang, lei zhang*, xin luan*, hong zhang*. bie-jia-ruan-mai-tang, a chinese medicine formula, inhibits retinal neovascularization in diabetic mice through inducing the apoptosis of retinal vascular endothelial cells. frontiers in cardiovascular medicine, 2022, 9: 959298. (if=5.846)
[4] wen-qing li, wen-hao liu, die qian, jia liu, shi-qiong zhou, lei zhang, wei peng*, li su*, hong zhang*. traditional chinese medicine: an important source for discovering candidate agents against hepatic fibrosis. frontiers in pharmacology, 2022, 13: 962525. (if=5.988)
[5] pei an†, dong lu†, lijun zhang, haiyue lan, hongxuan yang, guangbo ge, wei liu, weixing shen, xianting ding, dongxin tang, weidong zhang, xin luan*, haibo cheng*, hong zhang*. synergistic antitumor effects of compound-composed optimal formula from aidi injection on hepatocellular carcinoma and colorectal cancer. phytomedicine, 2022, 103:154231. (if=6.656)
[6] yu-ying chen, qiu-ping liu, pei an, min jia, xin luan*, jian-yuan tang*, hong zhang*. ginsenoside rd: a promising natural neuroprotective agent. phytomedicine, 2022, 95:153883. (if=6.656)
[7] qiu-ping liu†, jia-yi lin†, pei an, yu-ying chen, xin luan*, hong zhang*. lncrnas in tumor microenvironment: the potential target for cancer treatment with natural compounds and chemical drugs. biochemical pharmacology, 2021, 193:114802. (if=6.1)
[8] pei an, li-jun zhang, wei peng, yu-ying chen, qiu-ping liu, xin luan*, hong zhang*. natural products are an important source for proteasome regulating agents. phytomedicine, 2021, 93:153799. (if=6.656)
[9] yuan-yuan yu#, qiu-ping liu#, meng-ting li, pei an, yu-ying chen, xin luan*, chao lv*, hong zhang*. hu-zhang-qing-mai-yin inhibits proliferation of human retinal microvascular endothelial cells exposed to high glucose. frontiers in pharmacology, 2021, 12: 732655. (if=5.988)
[10] gang gong#, yu-li shen#, hai-yue lan#, jin-mei jin, pei an, li-jun zhang, li-li chen, wei peng*, xin luan*, hong zhang*. the cyr61 is a potential target for rotundifuran, a natural labdane-type diterpenes from vitex trifolia l., to trigger apoptosis of cervical cancer cells. oxidative medicine and cellular longevity, 2021, article id 6677687. (if=7.31)
[11] ting yang, yi-xin jiang, ye wu, dong lu, rui huang, long-ling wang, shi-qi wang, yingyun guan*, hong zhang*, xin luan*. resibufogenin suppresses triple-negative breast cancer angiogenesis by blocking vegfr2-mediated signaling pathway. frontiers in pharmacology, 2021, 682735. (if=5.988)
[12] mengting li#, jia ke#, yiqing deng, chunxiang chen, yichen huang, yuefeng bian, shufen guo, yang wu, hong zhang*, mingyuan liu*, yan han*. the protective effect of liquiritin in hypoxia/reoxygenation-induced disruption on blood brain barrier. frontiers in pharmacology, 2021, 671783. (if=5.988)
[13] hai-yue lan#, pei an#, qiu-ping liu, yu-ying chen, yuan-yuan yu, xin luan*, jian-yuan tang*, hong zhang*. aidi injection induces apoptosis of hepatocellular carcinoma cells through the mitochondrial pathway. journal of ethnopharmacology, 2021, 274, 114073. (if=5.195)
[14] gang gong†, ying-yun guan†, zhong-lin zhang, khalid rahman, su-juan wang, shuang zhou*, xin luan*, hong zhang*. isorhamnetin: a review of pharmacological effects. biomedicine & pharmacotherapy, 2020, 128, 110301. (if=7.419)
[15] xin luan†, li-jun zhang†, xiao-qin li, khalid rahman, hong zhang*, hong-zhuan chen*, wei-dong zhang*. compound-based chinese medicine formula: from discovery to compatibility mechanism. journal of ethnopharmacology, 2020, 254:112687. (if=5.195)
[16] xiao-qin li, jian-yong zhu, rong-rong pan, yu-li shen, khalid rahmand, chun-yan zhang, li-jun zhang*, xin luan*, hong zhang*. therapeutic effect of dongbai-tonglin-fang, a chinese herbal formula, on urinary tract infection in rat model. journal of ethnopharmacology, 2019 sep 15;241:112028. doi: 10.1016/j.jep.2019.112028. (if=5.195)
[17] hong zhang, qing-feng tang, meng-yao sun, chun-yan zhang, jian-yong zhu, yu-li shen, bin zhao, zhi-yi shao, li-jun zhang*, hong zhang*. arhgap9 suppresses the migration and invasion of hepatocellular carcinoma cells through up-regulating foxj2/e-cadherin. cell death & disease, 2018, 9(9):916. (if=9.685)